首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma
【24h】

Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma

机译:肾癌小鼠模型中的异常上皮形态和持续表皮生长因子受体信号转导

获取原文
获取原文并翻译 | 示例
           

摘要

The epidermal growth factor receptor (EGFR) has frequently been implicated in hyperproliferative diseases of renal tubule epithelia. We have shown that the NF2 tumor suppressor Merlin inhibits EGFR internalization and signaling in a cell contact-dependent manner. Interestingly, despite the paucity of recurring mutations in human renal cell carcinoma (RCC), homozygous mutation of the NF2 gene is found in ≈2% of RCC patient samples in the Sanger COSMIC database. To examine the roles of Merlin and EGFR in kidney tumorigen-esis, we generated mice with a targeted deletion of Nf2 in the proximal convoluted epithelium using a Villin-Cre transgene. All of these mice developed intratubular neoplasia by 3 months, which progressed to invasive carcinoma by 6-10 months. Kidneys from these mice demonstrated marked hyperproliferation and a concomitant increase in label-retaining putative progenitor cells. Early lumen-filling lesions in this model exhibited hyperactivation of EGFR signaling, altered solubility of adherens junctions components, and loss of epithelial polarity. Renal cortical epithelial cells derived from either early or late lesions were dependent on EGF for in vitro proliferation and were arrested by pharmacologic inhibition of EGFR or re-expression of Nf2. These cells formed malignant tumors upon s.c. injection into immunocompromised mice before in vitro passage. Treatment of Vil-Cre;Nf2~(lox/lox) mice with the EGFR inhibitor erlotinib halted the proliferation of tumor cells. These studies give added credence to the role of EGFR signaling and perhaps Nf2 deficiency in RCC and describe a rare and valuable mouse model for exploring the molecular basis of this disease.
机译:表皮生长因子受体(EGFR)经常与肾小管上皮过度增生性疾病有关。我们已经表明,NF2肿瘤抑制因子Merlin以细胞接触依赖性的方式抑制EGFR的内在化和信号传导。有趣的是,尽管在人类肾细胞癌(RCC)中很少出现重复突变,但在Sanger COSMIC数据库中约2%的RCC患者样品中发现了NF2基因的纯合突变。为了检查Merlin和EGFR在肾脏肿瘤发生中的作用,我们使用Villin-Cre转基因产生了在近端卷曲上皮中具有Nf2靶向缺失的小鼠。所有这些小鼠在3个月内发展为肾小管内瘤变,在6-10个月内发展为浸润性癌。这些小鼠的肾脏表现出明显的过度增殖,并伴随着标记保留的祖细胞的增加。在该模型中,早期的管腔充盈病变表现出EGFR信号的过度激活,粘附连接成分溶解度的改变以及上皮极性的丧失。源自早期或晚期病变的肾皮质上皮细胞在体外增殖方面依赖于EGF,并通过EGFR的药理抑制作用或Nf2的重新表达而被阻滞。这些细胞在皮下形成恶性肿瘤。在体外传代前将其注射入免疫受损的小鼠体内。用EGFR抑制剂厄洛替尼治疗Vil-Cre; Nf2〜(lox / lox)小鼠可阻止肿瘤细胞的增殖。这些研究为RCC中EGFR信号转导的作用以及Nf2缺乏提供了新的证据,并描述了一种罕见且有价值的小鼠模型,用于探索该疾病的分子基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号